JP7767008B2 - Oral composition - Google Patents

Description

This disclosure relates to oral compositions and components contained in oral compositions. The contents of all documents cited in this specification are incorporated herein by reference.

Oral compositions often contain bactericides to enhance their bactericidal effect in the oral cavity. Various ingredients are known to be used as bactericides in oral compositions, including anionic surfactants.

Japanese Patent Application Laid-Open No. 2018-002719

However, when an oral composition is applied to the oral cavity, the antiseptic agent contained in the oral composition is affected by components in saliva, reducing its antiseptic effect.

The inventors therefore attempted to develop a means to prevent the bactericidal effect of bactericides, particularly anionic surfactants, from being reduced by the influence of saliva.

The inventors discovered that by incorporating nicotinic acid or a derivative thereof in addition to an anionic surfactant into an oral composition, the antibacterial effect of the anionic surfactant may be less likely to be reduced by saliva, and they continued to make further improvements.

The present disclosure includes, for example, the subject matter described in the following sections:
Item 1.
An oral composition comprising (i) an anionic surfactant having a C10 to C18 linear carbon chain, and (ii) nicotinic acid or a derivative thereof.
Item 2.
(i) is represented by formula (1-1):
R-(CH ₂ ) _n CH ₃ (1-1)
(In formula (1-1), n represents an integer of 9 to 17, and R represents
Formula (A):

(wherein M represents Na or K, and m represents 1 or 2),
Formula (B):

(wherein M represents Na or K, and p represents an integer of 0 to 16),
Formula (C):

(wherein M represents Na or K),
Formula (D):

(wherein M represents Na or K),
Formula (E):

(wherein M represents Na or K, q is the same or different and represents an integer of 12 to 16, and n is the same as above),
Formula (F):

(wherein M represents Na or K), or a group represented by formula (G):

(wherein M represents Na or K)
and a compound represented by the formula:
Formula (1-2):
R-(CH ₂ ) _a -CH=CH-(CH ₂ ) _b CH ₃ (1-2)
(In formula (1-2), a represents an integer of 0 to 15, b represents an integer of 0 to 15 (7≦a+b≦15), and R is the same as above.)
At least one compound selected from the group consisting of compounds represented by
Item 1. The composition according to item 1.
Item 3.
Item 2. The composition according to Item 1, wherein (i) is at least one compound selected from the group consisting of sodium lauryl sulfate, sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, sodium myristoyl sarcosinate, sodium myristoyl sarcosinate, sodium lauroyl methyl alanine, sodium palmitoyl methyl alanine, sodium laureth sulfate, disodium polyoxyethylene alkyl (12-14) sulfosuccinate, sodium lauroyl methyl taurate, sodium cocoyl methyl taurate, sodium myristoyl methyl taurate, sodium palmitoyl methyl taurate, polyoxyethylene alkyl (12-16) ether phosphate, sodium lauroyl glutamate, sodium myristoyl glutamate, sodium palmitoyl glutamate, and sodium tetradecene sulfonate.
Item 4.
(ii) is at least one compound selected from the group consisting of nicotinic acid, 2-hydroxynicotinic acid, isonicotinic acid, 2-chloronicotinic acid, and methyl nicotinate;
Item 4. The composition according to any one of Items 1 to 3.
Item 5.
Item 5. The composition according to any one of Items 1 to 4, which is an oral sterilization composition.
Item 6.
An oral bactericidal activity enhancer for an anionic surfactant having a C10 to C18 linear carbon chain, which comprises nicotinic acid or a derivative thereof.

An oral composition is provided in which the bactericidal effect of the contained anionic surfactant is not easily reduced by components in saliva. It also provides an agent that enhances the bactericidal effect of the anionic surfactant in the oral cavity.

Each embodiment included in the present disclosure will be described in more detail below. The present disclosure preferably includes oral compositions and agents that enhance the bactericidal effect of anionic surfactants in the oral cavity, but is not limited to these. The present disclosure includes all of the disclosures herein that would be recognized by a person skilled in the art.

The oral composition included in the present disclosure contains (i) an anionic surfactant having a C10 to C18 linear carbon chain, and (ii) nicotinic acid or a derivative thereof. Hereinafter, this oral composition included in the present disclosure may be referred to as the "oral composition of the present disclosure." The anionic surfactant having a C10 to C18 linear carbon chain may be referred to as component (i). Nicotinic acid or a derivative thereof may be referred to as component (ii).

The C10 to C18 linear carbon chain in component (i) may be saturated or unsaturated. If it is unsaturated, it preferably has one or two carbon-carbon double bonds, and more preferably one carbon-carbon double bond.

Component (i), that is, anionic surfactants having a linear carbon chain of C10 to C18 (C10, C11, C12, C13, C14, C15, C16, C17, or C18), include surfactants represented by formula (1-1):
R-(CH ₂ ) _n CH ₃ (1-1)
Preferred examples of the compound include compounds represented by the following formula:

n represents an integer between 9 and 17 (9, 10, 11, 12, 13, 14, 15, 16, or 17).

Furthermore, the formula (1-2):
R-(CH ₂ ) _a -CH=CH-(CH ₂ ) _b CH ₃ (1-2)
Preferred examples of the compound include compounds represented by the following formula:

a is an integer between 0 and 15, and b is an integer between 0 and 15 (provided that 7≦a+b≦15). In other words, in the range where a+b=7, 8, 9, 10, 11, 12, 13, 14, or 15, a can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15, and b can be 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, or 15. A particularly preferred combination of (a, b) is, for example, (a, b)=(4, 7).

In addition, R in the formula (1-1) and the formula (1-2) is preferably, for example,
Formula (A):

(wherein M represents Na or K, and m represents 1 or 2),
Formula (B):

(wherein M represents Na or K, and p represents an integer of 0 to 16),
Formula (C):

(wherein M represents Na or K),
Formula (D):

(wherein M represents Na or K),
Formula (E):

(wherein M represents Na or K, q is the same or different and represents an integer of 12 to 16, and n is the same as above),
Formula (F):

(wherein M represents Na or K), or
Formula (G):

(wherein M represents Na or K).

As mentioned above, p represents 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, or 16, and q represents 12, 13, 14, 15, or 16. Furthermore, when R is a group represented by formula (E), there are two n's in formula (1-1), and in this case, the n's may be the same or different, and are preferably the same.

More specific examples of component (i) include sodium lauryl sulfate, sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, sodium myristoyl sarcosinate, sodium myristoyl sarcosinate, sodium lauroyl methyl alanine, sodium palmitoyl methyl alanine, sodium laureth sulfate, disodium polyoxyethylene alkyl (12-14) sulfosuccinate, sodium lauroyl methyl taurate, sodium cocoyl methyl taurate, sodium myristoyl methyl taurate, sodium palmitoyl methyl taurate, polyoxyethylene alkyl (12-16) ether phosphate, sodium lauroyl glutamate, sodium myristoyl glutamate, sodium palmitoyl glutamate, and sodium tetradecene sulfonate.

The compound of component (i) can be used alone or in combination of two or more.

Preferred examples of nicotinic acid derivatives in component (ii), i.e., nicotinic acid or a derivative thereof, include 2-hydroxynicotinic acid, isonicotinic acid, 2-chloronicotinic acid, and methyl nicotinate. Compounds of component (ii) can be used alone or in combination of two or more.

In the oral composition of the present disclosure, it is preferable that 0.05 to 10 parts by mass of component (ii) be contained per 1 part by mass of component (i). The upper or lower limit of this range (0.05 to 10 parts by mass) can be, for example, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, 1.9, 2, 2.1, 2.2, 2.3, 2.4, 2.5, 2.6, 2.7, 2.8, 2.9, 3, 3.1, 3.2, 3.3, 3.4, 3.5, 3.6, 3.7, 3.8, 3.9, 4, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7 ... 8, 4.9, 5, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6, 6.1, 6.2, 6.3, 6.4, 6.5, 6.6, 6.7, 6.8, 6.9, 7, 7.1, 7.2, 7.3, 7.4, 7.5, 7.6, 7.7, 7.8, 7.9, 8, 8.1, 8.2, 8.3, 8.4, 8.5, 8.6, 8.7, 8.8, 8.9, 9, 9.1, 9.2, 9.3, 9.4, 9.5, 9.6, 9.7, 9.8, or 9.9 parts by mass. For example, the range may be 0.1 to 9.

Furthermore, in the oral composition of the present disclosure, component (i) is preferably contained in an amount of approximately 0.05 to 2% by mass. The upper or lower limit of this range (0.05 to 2% by mass) may be, for example, 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 1.1, 1.2, 1.3, 1.4, 1.5, 1.6, 1.7, 1.8, or 1.9% by mass. For example, the range may be 0.1 to 1.5% by mass.

In addition, the oral composition of the present disclosure preferably contains approximately 0.01 to 1% by mass of component (ii). The upper and lower limits of this range (0.01 to 1% by mass) are, for example, 0.02, 0.03, 0.04, 0.05, 0.06, 0.07, 0.08, 0.09, 0.1, 0.11, 0.12, 0.13, 0.14, 0.15, 0.16, 0.17, 0.18, 0.19, 0.2, 0.21, 0.22, 0.23, 0.24, 0.25, 0.26, 0.27, 0.28, 0.29, 0.3, 0.31, 0.32, 0.33, 0.34, 0.35, 0.36, 0.37, 0.38, 0.39, 0.4, 0.41, 0.42, 0.43, 0.44, 0.45, 0.46, 0.47, 0.48, 0. 49, 0.5, 0.51, 0.52, 0.53, 0.54, 0.55, 0.56, 0.57, 0.58, 0.59, 0.6, 0.61, 0.62, 0.63, 0.64, 0.65, 0.66, 0.67, 0.68, 0.69, 0.7, 0.71, 0.72, 0.73, 0.74, 0.75, The concentration may be 0.76, 0.77, 0.78, 0.79, 0.8, 0.81, 0.82, 0.83, 0.84, 0.85, 0.86, 0.87, 0.88, 0.89, 0.9, 0.91, 0.92, 0.93, 0.94, 0.95, 0.96, 0.97, 0.98, or 0.99% by mass. For example, the range may be 0.02 to 0.9% by mass. Although not particularly limited, when a nicotinic acid derivative is used as component (ii), the concentration is preferably approximately 0.1 to 0.5% by mass.

The oral composition of the present disclosure can be manufactured by known methods or methods that can be easily derived from known methods. The oral composition of the present disclosure can also be used, for example, as a pharmaceutical, quasi-drug, or cosmetic. The form of the oral composition of the present disclosure is not particularly limited, and can be in the form (dosage form) of, for example, an ointment, paste, paste, gel, liquid, spray, mouthwash, liquid dentifrice, toothpaste, or topical agent.

In addition to components (i) and (ii), the oral composition of the present disclosure may further contain optional components that can be incorporated into oral compositions, either alone or in combination of two or more, as long as the effects of the present invention are not impaired.

For example, surfactants other than component (i), such as nonionic surfactants and/or amphoteric surfactants, can be further blended. Specific examples of nonionic surfactants include sugar fatty acid esters such as sucrose fatty acid esters, maltose fatty acid esters, and lactose fatty acid esters; fatty acid alkanolamides; sorbitan fatty acid esters; fatty acid monoglycerides; polyoxyethylene alkyl ethers having a polyoxyethylene addition coefficient of 8 to 10 and an alkyl group having 13 to 15 carbon atoms; polyoxyethylene alkylphenyl ethers having a polyoxyethylene addition coefficient of 10 to 18 and an alkyl group having 9 carbon atoms; diethyl sebacate; polyoxyethylene hydrogenated castor oil; fatty acid polyoxyethylene sorbitan; and alkyl glucosides having an alkyl group having 8 to 16 carbon atoms. Examples of zwitterionic surfactants include acetate betaine surfactants such as lauryl dimethylamino acetic acid betaine and coconut oil fatty acid amidopropyl dimethylamino acetic acid betaine; imidazoline surfactants such as N-cocoyl-N-carboxymethyl-N-hydroxyethylethylenediamine sodium; and amino acid surfactants such as N-lauryl diaminoethylglycine. Other preferred examples include coconut oil fatty acid monoethanolamide, coconut oil fatty acid diethanolamide, coconut oil fatty acid amidobetaine, coconut oil fatty acid amidopropyl betaine, and N-coconut oil fatty acid acyl L-arginine ethyl dl-pyrrolidonecarboxylate. These surfactants can be used alone or in combination of two or more.

Sweeteners such as saccharin sodium, acesulfame potassium, stevioside, sucralose, neohesperidyl dihydrochalcone, perillartine, thaumatin, aspartyl phenylalanyl methyl ester, and p-methoxycinnamic aldehyde may also be added. These may be used alone or in combination of two or more. These may be added in an amount of, for example, 0.01 to 1% by mass of the total composition.

In addition, binders that can be used alone or in combination of two or more include cellulose derivatives such as sodium carboxymethylcellulose, carboxymethylethylcellulose salts, hydroxyethylcellulose, hydroxypropylcellulose, and hydroxypropylmethylcellulose; microbially produced polymers such as xanthan gum and gellan gum; natural polymers or natural rubbers such as tragacanth gum, karaya gum, gum arabic, carrageenan, and dextrin; synthetic polymers such as polyvinyl alcohol and polyvinylpyrrolidone; inorganic binders such as thickening silica and Veegum; and cationic binders such as O-[2-hydroxy-3-(trimethylammonio)propyl]hydroxyethylcellulose chloride.

In addition, sorbitol, glycerin, propylene glycol, xylitol, maltitol, lactite, polyoxyethylene glycol, etc. can be blended alone or in combination of two or more types as humectants.

Preservatives that can be used include parabens such as methylparaben, ethylparaben, propylparaben, and butylparaben, sodium benzoate, phenoxyethanol, and alkyldiaminoethylglycine hydrochloride, either alone or in combination of two or more.

Coloring agents may include legal pigments such as Blue No. 1, Yellow No. 4, Red No. 202, and Green No. 3, mineral pigments such as ultramarine, enhanced ultramarine, and Prussian blue, and titanium oxide, either alone or in combination of two or more.

pH adjusters such as citric acid, phosphoric acid, malic acid, pyrophosphoric acid, lactic acid, tartaric acid, glycerophosphoric acid, acetic acid, nitric acid, or chemically acceptable salts thereof, or sodium hydroxide may be added. These may be added alone or in combination of two or more so that the pH of the composition is in the range of, for example, 4 to 9, preferably 5 to 8. The amount of pH adjuster added is, for example, 0.01 to 2% by weight.

Examples of medicinal ingredients include cationic disinfectants such as cetylpyridinium chloride, benzalkonium chloride, benzethonium chloride, chlorhexidine hydrochloride, and chlorhexidine gluconate; amphoteric disinfectants such as dodecyldiaminoethylglycine; nonionic disinfectants such as triclosan and isopropylmethylphenol; and hinokitiol. Furthermore, medicinal ingredients other than disinfectants can also be added. For example, aluminum lactate, potassium nitrate, vitamin E compounds such as dl-α-tocopherol acetate, tocopherol succinate, and tocopherol nicotinate, sodium fluoride, β-glycyrrhetinic acid, and dipotassium glycyrrhizinate may be added. The medicinal ingredients can be added alone or in combination of two or more.

Furthermore, as bases, for example, alcohols, silicone, apatite, white petrolatum, paraffin, liquid paraffin, microcrystalline wax, squalane, plastibase, etc. can be added alone or in combination of two or more.

Note that the above optional ingredients are examples and do not limit the optional ingredients that can be used.

The oral composition of the present disclosure contains component (ii), which inhibits the reduction in the bactericidal activity of component (i) due to saliva. Therefore, the time required for sterilization is shorter than when component (ii) is not contained. This makes it possible to shorten the time required for oral care. Furthermore, the bactericidal activity of component (i) is preferably used in oral compositions to sterilize, for example, periodontal disease bacteria. Therefore, although not particularly limited, the oral composition of the present disclosure can also be preferably used for subjects (particularly periodontal disease patients) who carry periodontal disease bacteria in their oral cavity. Furthermore, because the reduction in the bactericidal activity of component (i) due to saliva varies from person to person (for example, some people experience a significant reduction in the bactericidal activity of component (i) due to saliva, while others experience a mild reduction), the oral composition of the present disclosure can be preferably used for subjects in which the reduction in the bactericidal activity of component (i) due to saliva is desired (more specifically, for example, subjects in which the bactericidal activity of component (i) is reduced by saliva, subjects suffering from oral diseases caused by bacteria such as periodontal disease, etc.), although not particularly limited. Furthermore, subjects include not only humans but also non-human mammals. For example, pets and livestock can be included. More specifically, for example, dogs, cats, monkeys, cows, horses, pigs, sheep, goats, mice, rats, etc. can be included.

The present disclosure also encompasses a method for inhibiting the reduction in the bactericidal activity of component (i) caused by saliva, which involves using a combination of component (i) and component (ii), as well as a method for producing an oral composition, which involves incorporating component (i) and component (ii) into a composition.

Furthermore, the present disclosure also includes an oral bactericidal activity enhancer of component (i), which comprises component (ii). This oral bactericidal activity enhancer can be particularly preferably used as an oral bactericidal time shortener.

In this specification, the term "comprising" includes "consisting essentially of" and "consisting of." Furthermore, the present disclosure encompasses all arbitrary combinations of the constituent elements described in this specification.

Furthermore, the various characteristics (properties, structures, functions, etc.) described for each embodiment of the present disclosure above may be combined in any way to identify the subject matter encompassed by the present disclosure. In other words, the present disclosure encompasses all subject matter consisting of any combination of the combinable characteristics described in this specification.

The following examples are provided to explain embodiments of the present disclosure in more detail, but the embodiments of the present disclosure are not limited to the examples below.

Saliva collection: Each subject (subject A or B) brushed their teeth with a dentifrice containing neither surfactant nor bactericide, and 10 mL of saliva (non-irritating saliva) was collected. The collected saliva was stored in a refrigerator, and immediately before use, it was drawn in and discharged five times using a 23G needle and a 10 mL syringe (both manufactured by Terumo Corporation).

Preparation of Test Drug Solutions Test drug solutions were prepared containing 0.05 to 2% (w/v) of each compound belonging to component (i) and 0.01 to 1% (w/v) of each compound belonging to component (ii). For the preparation of the test drug solutions, aqueous solutions were prepared and used for the solutions containing nicotinic acid, isonicotinic acid, methyl nicotinate, and nicotinamide. For the solutions containing 2-hydroxynicotinic acid and 2-chloronicotinic acid, DMSO solutions with a final concentration of 5% (v/v) were prepared and diluted 10-fold with water.

The concentrations of all test drug solutions are shown in % (w/v), but because this is almost the same as the % (w/w) value (the % (w/w) is only slightly larger), it can also be interpreted as % (w/w) (i.e., mass %). More specifically, for example, since the density of a 5% (v/v) DMSO solution calculated according to JIS K 9702 and JIS Z 8804 is 0.994 g/ ^cm3 , the concentration of 0.1% (w/v) 2-hydroxynicotinic acid and 2-chloronicotinic acid can be calculated to be 0.10060362 mass%.

Bactericidal test: 200 μL of the test drug solution was dispensed into row A of a 96-well plate, and 200 μL of TSB/Y/VH medium was dispensed into rows B to H for inactivating the bactericidal action of the anionic surfactant and for culturing oral bacteria.

Since TSB/Y/VH medium can inactivate the bactericidal action of anionic surfactants, the sterilization time can be adjusted by adjusting the timing of addition of the medium. TSB/Y/VH medium was prepared by dissolving 30 g of Trypticase Soy Broth (TSB), 1 g of Yeast Extract, 1 g of Hemin/menadion solution, 0.7 g of lecithin, and 5 g of Tween 80 in distilled water, making up to 1 L, and autoclaving the resulting solution. The Hemin/menadion solution was prepared by dissolving 0.25 g of Hemin in 5 ml of 1N NaOH, adding 20 ml of distilled water, and then mixing with 0.025 g of menadion (Vitamin K3) dissolved in 25 ml of 99% ethanol.

20 μL of saliva was added to column A and pipetted, after which 20 μL was added at each time interval from column A to columns B through H. More specifically, the measurement started when 20 μL of saliva was added to column A and mixed by pipetting. 20 μL of the solution from column A was then added to column B after 30 seconds, column C after 60 seconds, column D after 90 seconds, column E after 120 seconds, column F after 180 seconds, column G after 240 seconds, and column H after 300 seconds, and mixed by pipetting. Anaerobic incubation was then performed for 48 hours using an Anaeropack Kenki (manufactured by Mitsubishi Gas Chemical Company, Inc.). Bacterial growth was visually confirmed and a live/dead state was determined. More specifically, if the medium became turbid upon visual inspection, it was determined that bacteria had grown and the bacteria in the solution had not been completely killed.

Each solution sampled from row A was evaluated after 30 seconds, 60 seconds, 90 seconds, 120 seconds, 180 seconds, 240 seconds, and 300 seconds, and the sterilization time was determined as the time when the medium first became non-turbid and the bacteria in the solution were killed.

The results are shown in Tables 1 and 2. Table 1 shows the sterilization time when each component (ii) was further added relative to the sterilization time for each subject's saliva when sodium lauryl sulfate used as component (i) alone was taken as 100%. Table 2 shows the sterilization time when nicotinic acid used as component (ii) was further added relative to the sterilization time for each subject's saliva when component (i) alone was taken as 100%. For example, if the sterilization time when 0.1% (w/v) sodium lauryl sulfate was mixed with subject A's saliva was 360 seconds, and the sterilization time when a test drug solution containing 0.1% (w/v) sodium lauryl sulfate and 0.1% (w/v) nicotinic acid was mixed with subject A's saliva was 180 seconds, the relative sterilization time in this case would be 50%.

An example formulation is shown below. Note that the numerical values (amounts) of each component listed in the table showing the example formulation are in mass %.

Claims (10)

(i) an anionic surfactant having a C10 to C18 linear carbon chain, and (ii) at least one compound selected from the group consisting of nicotinic acid, 2-hydroxynicotinic acid, isonicotinic acid, 2-chloronicotinic acid, and methyl nicotinate;
0.05 to 1.5% by mass of (i) and 0.01 to 1% by mass of (ii);
An oral composition comprising: (i) is represented by formula (1-1):
R-(CH ₂ ) _n CH ₃ (1-1)
(In formula (1-1), n represents an integer of 9 to 17, and R represents
Formula (A):
(wherein M represents Na or K, and m represents 1 or 2),
Formula (B):
(wherein M represents Na or K, and p represents an integer of 0 to 16),
Formula (C):
(wherein M represents Na or K),
Formula (D):
(wherein M represents Na or K),
Formula (E):
(wherein M represents Na or K, q is the same or different and represents an integer of 12 to 16, and n is the same as above),
Formula (F):
(wherein M represents Na or K), or a group represented by formula (G):
(wherein M represents Na or K)
and a compound represented by the formula:
Formula (1-2):
R-(CH ₂ ) _a -CH=CH-(CH ₂ ) _b CH ₃ (1-2)
(In formula (1-2), a represents an integer of 0 to 15, b represents an integer of 0 to 15 (7≦a+b≦15), and R is the same as above.)
At least one compound selected from the group consisting of compounds represented by
The composition of claim 1. The composition of claim 1, wherein (i) is at least one compound selected from the group consisting of sodium lauryl sulfate, sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, sodium myristoyl sarcosinate, sodium lauroyl methyl alanine, sodium palmitoyl methyl alanine, sodium laureth sulfate, disodium polyoxyethylene alkyl (12-14) sulfosuccinate, sodium lauroyl methyl taurate, sodium cocoyl methyl taurate, sodium myristoyl methyl taurate, sodium palmitoyl methyl taurate, polyoxyethylene alkyl (12-16) ether phosphate, sodium lauroyl glutamate, sodium myristoyl glutamate, sodium palmitoyl glutamate, and sodium tetradecene sulfonate. (i) is represented by formula (1-1):
R-(CH ₂ ) _n CH ₃ (1-1)
(In formula (1-1), n represents an integer of 9 to 17, and R represents
Formula (A):
(wherein M represents Na or K, and m represents 1 or 2),
Formula (B):
(wherein M represents Na or K, and p represents an integer of 0 to 16),
Formula (C):
(wherein M represents Na or K), or a group represented by formula (F):
(wherein M represents Na or K)
At least one compound selected from the group consisting of compounds represented by
The composition of claim 1. (i) is two or more compounds selected from the group
The composition according to any one of claims 2 to 4. The composition according to any one of claims 1 to 4, which is a composition for sterilizing the oral cavity. (i) an oral bactericidal potentiator of an anionic surfactant having a C10 to C18 linear carbon chain,
(ii) consisting of at least one compound selected from the group consisting of nicotinic acid, 2-hydroxynicotinic acid, isonicotinic acid, 2-chloronicotinic acid, and methyl nicotinate;
The composition for oral use is used by blending it so that (i) is contained in an amount of 0.05 to 1.5% by mass and (ii) is contained in an amount of 0.01 to 1% by mass.
Oral antibacterial agent. ( i) is represented by the formula (1-1):
R-(CH ₂ ) _n CH ₃ (1-1)
(In formula (1-1), n represents an integer of 9 to 17, and R represents
Formula (A):
(wherein M represents Na or K, and m represents 1 or 2),
Formula (B):
(wherein M represents Na or K, and p represents an integer of 0 to 16),
Formula (C):
(wherein M represents Na or K),
Formula (D):
(wherein M represents Na or K),
Formula (E):
(wherein M represents Na or K, q is the same or different and represents an integer of 12 to 16, and n is the same as above),
Formula (F):
(wherein M represents Na or K), or a group represented by formula (G):
(wherein M represents Na or K)
and a compound represented by the formula:
Formula (1-2):
R-(CH ₂ ) _a -CH=CH-(CH ₂ ) _b CH ₃ (1-2)
(In formula (1-2), a represents an integer of 0 to 15, b represents an integer of 0 to 15 (7≦a+b≦15), and R is the same as above.)
or two or more compounds selected from the group consisting of compounds represented by the formula:
The oral bactericidal activity enhancer according to claim 7 . ( i) is at least one compound selected from the group consisting of sodium lauryl sulfate, sodium lauroyl sarcosinate, sodium cocoyl sarcosinate, sodium myristoyl sarcosinate, sodium lauroyl methyl alanine, sodium palmitoyl methyl alanine, sodium laureth sulfate, disodium polyoxyethylene alkyl (12-14) sulfosuccinate, sodium lauroyl methyl taurate, sodium cocoyl methyl taurate, sodium myristoyl methyl taurate, sodium palmitoyl methyl taurate, polyoxyethylene alkyl (12-16) ether phosphate, sodium lauroyl glutamate, sodium myristoyl glutamate, sodium palmitoyl glutamate, and sodium tetradecene sulfonate, or two or more compounds selected from the group;
The oral bactericidal activity enhancer according to claim 8 . ( i) is represented by the formula (1-1):
R-(CH ₂ ) _n CH ₃ (1-1)
(In formula (1-1), n represents an integer of 9 to 17, and R represents
Formula (A):
(wherein M represents Na or K, and m represents 1 or 2),
Formula (B):
(wherein M represents Na or K, and p represents an integer of 0 to 16),
Formula (C):
(wherein M represents Na or K), or a group represented by formula (F):
(wherein M represents Na or K)
or two or more compounds selected from the group consisting of compounds represented by the formula:
The oral bactericidal activity enhancer according to claim 8 .